Servier Archives

News and Trends 3 Nov 2022

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […]

November 3, 2022 - 2 minutesmins - By Jim Cornall

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is booming with billions of euros in investment. The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the […]

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

More News! 19 Sep 2018

This Liver Model Made With 4D Bioprinting Could Improve Drug Toxicity Testing

Poietis has partnered with the pharma company Servier to develop a 4D bioprinted liver model that could predict liver toxicity of drugs better than current methods. Liver toxicity testing is one of the key tests that are performed during preclinical trials with investigational drugs. “The role of the liver is to degrade substances toxic to […]

September 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […]

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 6 Jan 2017

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France’s biggest pharma companies, is offering up to €1.7B to US-based Pieris Pharmaceuticals. The team will initially develop five programs that can be later expanded to up to eight. For […]

January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here’s a list of the best success stories of 2016. Biotech is becoming a powerful driving force in medicine, providing innovative therapies that could end some of the most severe diseases. To celebrate the advances in the area of […]

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully ‘saving’ two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its lead candidate UCART-19. It’s once again a success for the French biotech company! As it announced on Monday, the first patient has been treated in […]

June 23, 2016 - 2 minutesmins - By Jerome Topsent

servier lonsurf colorectal cancer trifluridine tipiracil

News and Trends 28 Apr 2016

EU approves Combo-Drug for Metastatic Colorectal Cancer

Servier sees one of its combo-drug (trifluridine/tipiracil) approved by the European Commission, after showing a 2 month improvement in overall survival for metastatic Colorectal cancer. The largest private Pharma from France, Servier has well-known stake in innovative oncology therapies due to its role in the restructuring of Cellectis as a universal CAR-T Biotech – which looks extremely […]

April 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market. GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such […]

April 16, 2016 - 2 minutesmins - By Dani Bancroft

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing. The first therapy initially developed by […]

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

leukemia ucart19 cellectis cancer cart trial UK

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins…dubbed the ‘Miracle Cure’ for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French billion euro Biotech, Cellectis, submitted a clinical trial application to the Medicines & Healthcare products Regulatory Agency (MHRA). Specifically, the request was to approve initiation […]

January 4, 2016 - 2 minutesmins - By Dani Bancroft

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis’s leading product UCART19 for blood cancer. This unusual move only further feeds the rumours of Pfizer’s potential future acquisition of Cellectis. As we’ve discussed before, Cellectis has moved most […]

November 19, 2015 - 3 minutesmins - By Dani Bancroft

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us